Showing that it works in the UK healthcare pathway
Many have been successfully treated
IQoro is used by thousands of people to treat the symptoms of dysphagia – whether after stroke, head injury or for many other reasons. Additionally, patients use it to address reflux, GERD (GORD) and LPR, and snoring and Obstructive Sleep Apnoea. The evidence base is robust and clear – the treatment works!
Within the UK, healthcare professionals, the NHS, NICE and others highlight that most of these patients are either private individuals, or in healthcare systems in other countries.
Therefore, we need to address the question, ”Will IQoro work just as well in the UK healthcare pathway?” The physiology is similar across Sweden and the UK, but there may be differences in how it can be deployed in the two different healthcare systems.
At the end of 2017, it was apparent that there were a number of NHS and other UK institutions that wanted to get started on using the IQoro treatment with patients that matched the condition symptoms that it treats best. At the same time NICE asked for evidence of successful use in the UK NHS dysphagia healthcare pathway.
A dozen or so institutions decided to launch service evaluations where IQoro treatment could be introduced in a controlled way through a number of SLTs to a limited cohort of patients. That’s the IQEAP programme.
How can we help?
The service evaluations belong to the hospitals and institutions conducting them, not to IQoro. The leadership in the SLT groups decide the size and shape and details of their project.
When statring the programme, it soon became obvious that a lot of the initial questions were common across several institutions, and that a lot of wheels were being reinvented. “How do I explain to my R&D department why this is a service evaluation of IQoro and not a formal clinical study?”, “What exclusion and inclusion criteria do I want to apply?”, “How will I measure outcome measures and the SLT experience?”, “How do I map a healthcare pathway with and without IQoro intervention?” And more.
Below, we provide a list of example documents that you can use if you want to, that may make the process simpler for you, and your life easier. We hope this helps!
1. What is an IQEAP?
including why it is a service evaluation not a randomised control trial.
2. Inclusion and exclusion considerations
for IQoro treatment with dysphagia patients and others
4. IQoro® feasibility kit for healthcare professionals – agreement
The company supplies demo products for healthcare professionals to use in patient feasibility assessments. This is part of accredited IQEAP Service Evaluations. This agreement regulates the responsibilities from both sides when the IQoro products are supplied.
5. Infection control procedure for feasibility kits
IQoro® devices used for patient feasibility testing will need to be kept clean and ready-for-use. Here is a procedure recommended by one NHS SLT department.
6. Tips on how to introduce IQoro® to a patient
A guide for the professional that is about to commence deploying IQoro to patients.
7. Patient consent form
Optional – may be required by some departments.
8. How to train with your IQoro®
A very simplified ‘one page’ guide for the self-administered patient with functional lips and arms.
9. How to train with your IQoro® using a jaw grip
A simplified ‘one page’ guide for the self-administered patient with functional arms and hands, but weak lip strength.
10. I’m not sure I’m training properly
A step-by-step guide to the training process to be used as a troubleshooting guide for those not sure that they are getting it right.
11. How to assist someone to train with IQoro®
A guide for professionals and carers that will help a patient who has insufficient lip and arm strength.
12. A4-sized training diary sheet
A journal sheet is included in the booklet that comes with each device, but for some patients this larger version may be preferred.
13. Pre-Procurement Questionnaire
May be required by NHS for procurement purposes.
14. Scientific research behind IQoro® training
The entire library of scientific publications can be found on the website. This document reproduces the abstracts of a dozen or so of the relevant clinical studies, and may be useful for some audiences.
15. IQoro – How it works and the primacy of its neurological effect
Many SLTs using IQoro for the first time will be curious as to how it can be so effective in cases where patients have had problems for years after stroke, or how the device can address so many condition groups. This document, developed with the support of Dr Mary Hägg, explains the key role of the neurological effects of IQoro training.
16. IQEAP Patient experience
Records the progress of patient treatment as experienced by the patient.
17. IQEAP SLT experience
This document provides a record of how the SLT experienced the patient’s treatment with IQoro. It is shown here in text format, but is also made available to therapists on-line in a Survey Monkey. Records the progress of patient treatment as experienced by the SLT.
18. Therapy outcome measures and tools
NHS institutions use a variety of therapy outcome measures when assessing patients, including to test at baseline and end-of-treatment. The Royal College of Speech and Language Therapists have kindly provided this information to share.